Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI North America CPhI North America
Not Confirmed
Not Confirmed
20-22 May, 2025
World Vaccine Conferen...World Vaccine Conference
Not Confirmed
Not Confirmed
22-24 April, 2025
Not Confirmed
Not Confirmed
22-25 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI North America CPhI North America
Industry Trade Show
Not Confirmed
20-22 May, 2025
World Vaccine Conferen...World Vaccine Conference
Industry Trade Show
Not Confirmed
22-24 April, 2025
Industry Trade Show
Not Confirmed
22-25 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/how-trump-s-tariffs-on-imported-drugs-can-hurt-supply-chains-consumers-and-industry
07 Jan 2025
// BUSSINESSWIRE
https://www.businesswire.com/news/home/20250106155648/en/Candid-Therapeutics-Enters-into-Agreement-with-WuXi-Biologics-on-Trispecific-T-cell-Engager
16 Dec 2024
// BUSINESSWIRE
16 Dec 2024
// BUSINESSWIRE
16 Dec 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/nona-biosciences-announces-discovery-collaboration-with-candid-therapeutics-for-next-generation-t-cell-engagers-302332470.html
16 Oct 2024
// BUSINESSWIRE
Details:
CND106 is a BCMAxCD3 bispecific antibody designed to target and eliminate later stage B-cells which are responsible for producing harmful autoantibodies.
Lead Product(s): CND106
Therapeutic Area: Immunology Brand Name: CND106
Study Phase: Phase IProduct Type: Antibody
Sponsor: Venrock Healthcare Capital Partners
Deal Size: $370.0 million Upfront Cash: Undisclosed
Deal Type: Financing September 09, 2024
Lead Product(s) : CND106
Therapeutic Area : Immunology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Venrock Healthcare Capital Partners
Deal Size : $370.0 million
Deal Type : Financing
Candid Therapeutics Raises $370M to Evaluate Autoimmune Therapies Clinically
Details : CND106 is a BCMAxCD3 bispecific antibody designed to target and eliminate later stage B-cells which are responsible for producing harmful autoantibodies.
Product Name : CND106
Product Type : Antibody
Upfront Cash : Undisclosed
September 09, 2024
ABOUT THIS PAGE